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Purpose: There is a concern on which antimicrobials are appropriate as empirical 
agents for community-onset acute pyelonephritis (APN) in regions where the fluo-
roquinolone resistance rate is high, such as in Korea. Materials and Methods: 
Three hundred and two strains of E. coli in 2001-2002 and 349 strains in 2008-
2009 were isolated from the urine cultures of female adult APN patients, and the 
antimicrobial susceptibility was compared according to each study period. All the 
patients were classified as uncomplicated or complicated APN, and a subgroup 
analysis was done thereafter. Results: The E. coli strains isolated in 2008-2009 
showed improved susceptibility to trimethoprim-sulfamethoxazole compared to 
those isolated in 2001-2002. However, the third generation cephalosporin and gen-
tamicin susceptibility was worsened. Of the 232 isolates from the uncomplicated 
APN patients, there was no difference between the two different time periods. On 
the other hand, of the 419 isolates from the complicated APN patients, the suscep-
tibility to third generation cephalosporin, gentamicin and ciprofloxacin was signifi-
cantly worsened. Conclusion: The antimicrobial susceptibility of E. coli changed 
over the study period, however, this change occurred mainly in the complicated APN 
patients. In Korea, ciprofloxacin is still useful as an empirical agent for uncompli-
cated APN patients, but this is not the case for patients with complicated APN be-
cause of high resistance rate to ciprofloxacin in these patients. For the complicated 
APN patients, the rate of resistance to ciprofloxacin is already more than 30%.
Key Words:    Escherichia coli, antimicrobial resistance, acute pyelonephritis, cip-
rofloxacin resistance
INTRODUCTION
Acute pyelonephritis (APN) is a very common community infection in women. 
The mortality of APN is only 0.7%, which is not high compared to that of other 
community acquired infections such as pneumonia.1 Nevertheless, APN some-
times progresses to sepsis, uremia and multi-organ failure, and consequently, there 
can be dismal outcomes.2 APN patients usually suffer from systemic symptoms 
such as fever, malaise and/or vomiting, and this interferes with their daily living Change of Antimicrobial Susceptibility in E. coli 
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from January 2001 to December 2002 and the recent 2 year 
period was from January 2008 to December 2009. All the 
female patients over 16 years old who were diagnosed with 
APN and whose pathogen was confirmed to be E. coli by 
urine culture were enrolled in this study. The data were col-
lected at Ajou University Medical Center, which is a tertia-
ry care hospital with more than 1,100 beds and located in 
Suwon, Korea. The patients who were treated as outpatients 
or inpatients were all included. 
To exclude hospital-acquired infection, the urine cultures 
obtained within 48 hours after the first diagnosis of APN 
was made were included in this study. The patients who 
were admitted to the hospital or who resided more than 24 
hours in the emergency room within the previous 30 days 
were excluded. Healthcare-associated infections were ex-
cluded eliminating patients who were a resident in a nurs-
ing home or an extended care facility, patients who were 
under chronic dialysis within 30 days of the diagnosis or 
those patients who were being treated with home wound 
care or home infusion therapy.15 Patients who had a Foley 
catheter or a suprapubic catheter were also excluded. The 
repeated APN episodes of the same patients and that oc-
curred within 6 months from the first infection were ex-
cluded to remove the relapsed cases. 
This study was retrospectively performed by carefully re-
viewing the medical records and conducting an analysis of 
the antimicrobial susceptibility data of the clinical microbi-
ology laboratory at our hospital. This study was approved 
by the institutional review board at Ajou University Hospi-
tal (Protocol No; AJIRB-MED-MDB-10-223). All the data 
collected for this study were kept confidential.
Definitions
APN was defined as 1) at least one of the symptoms of a fe-
ver more than 38°C, urgency, frequency, dysuria or suprapu-
bic tenderness, 2) a positive dipstick for leukocyte esterase or 
nitrate or more than 10 white blood cells were observed on a 
high power microscopy field and 3) quantitative urine culture 
with bacterial growth of more than 105 CFU/mL.16 All these 
three conditions should be satisfied.16 ‘However, E. coli colo-
ny growth more than 104 CFU/mL was included if any anti-
microbial agent was previously administered before collect-
ing the urine culture.16 The specimen whose culture had more 
than 2 species of microorganisms was excluded, as it was 
judged to be an inappropriate specimen.
Generally, a complicated UTI was considered to be an in-
fection that occurs in the setting of any factor that predis-
and many of them often need hospitalization.3 Therefore, to 
treat APN, systemic antimicrobial therapy should be started 
without delay if a clinical diagnosis of APN is suspected. 
Several days are generally needed to identify the pathogen 
and to assess the antimicrobial susceptibility, therefore, em-
pirical treatment is quite important. It is well known that 
80-90% of the prevalent organisms in APN patients are 
Escherichia coli.4 Thus, precise information about the anti-
microbial susceptibility of the community strains of E. coli 
is essential for selecting proper empirical agents.5
The antimicrobial susceptibility of E. coli shows geo-
graphic differences, therefore, it is important to gather in-
formation about this susceptibility in regard to a specific 
country or region.6 The recent Korean studies that have fo-
cused on community-onset APN have reported higher resis-
tance rates to various antibiotics than those rates of North 
America or Europe.7-11 The rate of resistance to ciprofloxa-
cin was significantly high at 12.0-30.2%.7-11
In Korea, fluoroquinolone and third generation cephalo-
sporin have been widely used for the treatment of commu-
nity-onset APN.9,10,12 The cost of producing cephalosporins 
and fluoroquinolones and the amounts produced have con-
tinuously increased since the 1980s in Korea.13 It is well 
known that the increased use of specific antibiotics can re-
sult in the redistribution and increased resistance of the caus-
ative organisms.14 Thus, it is necessary to determine if there 
has been any change of the antimicrobial susceptibility of 
E. coli in the recent years. Especially, increased resistance 
to fluoroquinolone is a major concern. If the resistance of 
any antimicrobial agent is higher than 20%, the empirical 
use could then be regarded as an improper choice for the 
treatment of urinary tract infection (UTI) and alternative 
agents should be considered.5 
In this article, we report that there is distinct change of 
antimicrobial susceptibility of the community uropathogen-
ic strains of E. coli during the period of 2001-2009. The 
change has not equally affected all the APN patients, and it 
has proven to be a main concern for the complicated APN 
patients, who have a high risk of acquiring antimicrobial re-
sistant organisms. 
MATERIALS AND METHODS
　　　
Study design and population
A previous 2 year period and a recent 2 year period were 
selected for comparison; the previous 2 year period was Seung-Kwan Lim, et al.
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factor analysis for ciprofloxacin resistance are shown as 
odds ratio and 95% confidence intervals. Statistical signifi-
cance was set at p value <0.05 using two-sided comparisons. 
RESULTS
 
Study population
A total of 302 cases were identified from 292 patients who 
were diagnosed with APN by urine culture for E. coli in 
2001-2002. In 2008-2009, 349 cases of 338 patients were 
identified. None of the patients were enrolled more than 
twice. There was no statistically significant difference in the 
numbers of admitted patients, which included 239 inpatients 
of 392 cases (79.1%) in 2001-2002 and 260 patients of 357 
(74.5%) cases in 2008-2009 (p=0.163). There was no statis-
tical difference in the underlying disease, a history of ad-
mission in the recent 12 months and the antimicrobial agent 
administration in recent 6 months between the two groups 
(Table 1). However, the mean age of the cases in 2001-
2002 was younger than that in 2008-2009 (52.3 year-old vs. 
55.5 year-old, respectively; p=0.027).
Antimicrobial susceptibility 
The antimicrobial susceptibility testing results of E. coli were 
compared between the two different time periods (Fig. 1A). 
There was no difference in the antimicrobial susceptibility 
to ampicillin and the combination agents of aminopenicillin 
with beta-lactamase inhibitor. Trimethoprim-sulfamethoxa-
zole susceptibility was improved from 57.0% in 2001-2002 
to 67.9% in 2008-2009 as time passed by (p=0.004). Sus-
ceptibility to ciprofloxacin showed a trend of decrease from 
82.1% in 2001-2002 to 76.5% in 2008-2009, but this was not 
statistically significant (p=0.079). Susceptibility to imipen-
em was 100% in both periods. Gentamicin susceptibility 
was decreased from 83.8% to 76.2% (p=0.017). Amikacin 
susceptibility was quite good at 99.7% in 2001-2002 and 
100% in 2008-2009. The third generation cephalosporin 
susceptibility deteriorated as all the organisms except one 
isolate were susceptible to ceftriaxone in 2001-2002, but 17 
isolates were resistant to cefotaxime in 2008-2009 (99.7% 
vs. 95.1%, respectively; p<0.001). All 17 isolates were con-
firmed to be ESBL producing strains. 
Subgroup analysis
All the patients were classified into uncomplicated and 
complicated APN subgroups and a subgroup analysis was 
poses to the risk of serious complications or treatment fail-
ure.17 However, no true consensus has been reached within 
the medical community as to what specifically defines a 
complicated UTI.18 Ronald and Harding19 defined compli-
cated UTI as infections in patients with structural abnormal-
ities, metabolic and/or hormonal abnormalities, impaired 
host responses or infections with an unusual pathogen.
In this study, we defined complicated APN as acute py-
elonephritis combined with any other condition such as be-
ing more than 65 years old, diabetes mellitus, nephrologic 
diseases (chronic renal failure, glomerulonephritis, nephrot-
ic syndrome), malignancy, urolithiasis, urologic diseases 
(urologic malignancy, urologic surgery, ureter stricture, vesi-
co-ureteral reflux, polycystic kidney disease), neurogenic 
bladder, kidney transplant recipients, immune-compro-
mised hosts or pregnancy. 
Laboratory methods
Bacterial isolates were identified by biochemical profiling us-
ing the Vitek-2 system (bioMérieux, Marcy l’Etoile, France). 
Antimicrobial susceptibility testing was performed using 
the microdilution method according to the recommenda-
tions of the Clinical and Laboratory Standards Institute 
(CLSI).20 E. coli ATCC 25922 was used as the quality con-
trol strain. The interpretative criteria for each antimicrobial 
drug tested were those recommended by the CLSI. The ex-
tended spectrum beta-lactamase (ESBL) test was done us-
ing the Vitek-2 ESBL test.21 
A few of the antimicrobial drugs on the susceptibility 
testing of E. coli were changed from the first to the second 
study periods in our microbiology laboratory. In 2001-
2002, ampicillin-sulbactam had a place in the test antibiot-
ics, but it was replaced by amoxicillin-clavulanate in 2008-
2009. The testing for third generation cephalosporin in 
2001-2002 was for ceftriaxone, but it was also changed to 
cefotaxime in 2008-2009. 
Statistical methods
The antimicrobial susceptibility of the E. coli isolated dur-
ing the periods of 2001-2002 and the period of 2008-2009 
were compared. A subgroup analysis was also performed 
by dividing the APN into uncomplicated and complicated 
APN. The risk factors for acquiring ciprofloxacin resistance 
were also analyzed. Chi-square tests, Fisher’s exact test and 
Student’s t-test were used for the statistical analysis. The 
statistical analysis pack used was SPSS for windows (ver-
sion 12.0, SPSS, Chicago, IL, USA). The results of the risk Change of Antimicrobial Susceptibility in E. coli 
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Table 1. Comparison of Baseline Characteristics of APN Patients from 2001-2002 versus that of APN Patients 
from 2008-2009
Group
p value
2001-2002 n=302 (%) 2008-2009 n=349 (%)
Admission within 12 months   53 (17.5)   55 (15.8) 0.540
Antibiotics within 6 months 27 (8.9)   38 (10.9) 0.408
Complicated APN 184 (60.9) 235 (67.3) 0.089
    Age >65 yrs 106 (35.1) 145 (41.5) 0.054
    Diabetes mellitus   96 (31.8) 105 (30.1) 0.639
    Urolithiasis   6 (2.0)   9 (2.6) 0.616
    Nephrologic disease* 29 (9.6) 22 (6.3) 0.118
    Urologic disease
† 15 (5.0) 16 (4.6) 0.819
    Neurogenic bladder 25 (8.3) 30 (8.6) 0.884
    KT recipients   3 (1.0) 10 (2.9) 0.089
    Immunocompromised host   9 (3.0) 19 (5.4) 0.122
    Malignancy 24 (7.9) 19 (5.4) 0.200
    Pregnancy   5 (1.7)   7 (2.0) 0.741
APN, acute pyelonephritis; KT, kidney transplantation.
*Chronic renal failure, glomerulonephritis, nephrotic syndrome.
†Urologic malignancy, urologic surgery, ureter stricture, vesico-ureteral reflux, polycystic kidney disease.
Fig. 1. Comparison of the antimicrobial susceptibilities of the E. coli isolated between 2001-2002 versus that of 2008-2009. (A) All the study 
subjects (n=651). (B) The uncomplicated APN subgroup (n=232). (C) The complicated APN subgroup (n=419). The asterisk means a p val-
ue <0.05. AMC, ampicillin; AP-BLI, aminopenicillin and beta-lactamase inhibitor; GM, gentamicin; AMK, amikacin; SXT, trimethoprim-sul-
famethoxazole; CPFX, ciprofloxacin; 3Ceph, third generation cephalosporin; IMPM, imipenem. 
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cant difference between the two study periods (Fig. 1C). Cip-
rofloxacin susceptibility decreased from 78.8% in 2001-2002 
to 69.4% in 2008-2009 (p=0.030), and gentamicin suscepti-
bility decreased from 83.2% to 74.0% (p=0.025). The sus-
ceptibility to third generation cephalosporin was decreasing 
from 99.5% to 93.6% (p=0.001). However, the susceptibili-
ty of trimethoprim-sulfamethoxazole was improved from 
51.6% to 63.8% (p=0.012).
Risk factor analysis
All the 651 patients enrolled were analyzed for the risk fac-
tors to ciprofloxacin resistance (Table 2). Among them, the 
significant risk factors proved to be antimicrobial adminis-
tration in recent 6 months, diabetes mellitus, urolithiasis and 
a neurogenic bladder. Complicated APN itself was set as a 
variable and the risk of ciprofloxacin resistant E. coli infec-
tion was analyzed. Result showed that the odds ratio was 
high at 2.98 (95% confidence interval: 1.868-4.766), and 
that complicated APN had a clear relationship with cipro-
floxacin resistant E. coli infection (p<0.001).
DISCUSSION
Increasing resistance of pathogenic E. coli is a world-side 
phenomenon of the past two or three decades.22-24 Trime-
thoprim-sulfamethoxazole were suggested as standard ther-
apeutic agents in the past, but the E. coli resistance was al-
ready higher than 20% in North America during the 1990s.25 
then done. There were 118 uncomplicated APN patients in 
2001-2002 and 114 in 2008-2009. There were 184 compli-
cated APN patients in 2001-2002 and 235 in 2008-2009. 
The mean age of the uncomplicated APN patients was 
not different between the two groups, which was 38.7 year-
old in 2001-2002 and 39.9 year-old in 2008-2009 (p=0.488). 
Admission within 12 months and any antibiotic administra-
tion within 6 months were not different between the two 
groups. 
The complicated APN patient group for the antibiotic ad-
ministration and the admission history in 2001-2002 was not 
different from the complicated APN patient group in 2008-
2009. The mean age of these two groups was not statistically 
different (61.0 and 63.1 year-old, respectively; p=0.183). The 
underlying diseases except nephrologic diseases were not 
different either (data not shown). Nephrologic diseases were 
more common among the subjects of the 2001-2002 year pe-
riod (15.8% in 2001-2002 vs. 9.4% in 2008-2009, respec-
tively; p=0.047).
In the group with uncomplicated APN, there was no sig-
nificant change of antimicrobial susceptibility of the E. coli 
when the different periods were compared (Fig. 1B). The 
bacteria showed an increasing trend for susceptibility to tri-
methoprim-sulfamethoxazole (65.5% in 2001-2002 and this 
changed to 76.3% in 2008-2009), but this was not statisti-
cally significant (p=0.064). The ciprofloxacin susceptibility 
was 87.3% in 2001-2002 and changed to 91.2% in 2008-
2009, but this was not significant. 
On the other hand, complicated APN showed a signifi-
Table 2. Comparison of the Risk Factors between the Ciprofloxacin Resistant and Susceptible E. coli  
Cirpofloxacin resistant 
E. coli  n=136 (%)
Ciprofloxacin susceptible 
E. coli  n=515 (%) OR (95% CI) p value
Admission within 12 months   30 (22.1)   78 (15.1) 1.57 (0.990-2.541)   0.054
Antibiotics within 6 months   25 (18.4) 40 (7.8) 2.68 (1.557-4.593) <0.001
Complicated APN 111 (81.6) 308 (59.8) 2.98 (1.868-4.766) <0.001
    Age >65 yrs   58 (42.6) 193 (37.5) 1.24 (0.845-1.821)   0.270
    Diabetes mellitus   54 (39.7) 147 (28.5) 1.65 (1.113-2.443)   0.012
    Urolithiasis   7 (5.1)   8 (1.6) 3.44 (1.225-9.658)   0.013
    Nephrologic disease*   16 (11.8) 35 (6.8) 1.83 (0.979-3.414)   0.055
    Urologic disease
† 15 (8.2) 16 (6.8) 1.87 (0.858-4.065)   0.111
    Neurogenic bladder   26 (19.1) 29 (5.6) 3.96 (2.244-6.993) <0.001
    KT recipients   4 (2.9)   9 (1.7) 1.70 (0.517-5.619)   0.376
    Immunocompromised host   9 (6.6) 19 (3.7) 1.85 (0.817-4.187)   0.134
    Malignancy 13 (9.6) 30 (5.8) 1.71 (0.856-3.373)   0.119
    Pregnancy   2 (1.5) 10 (1.9) 0.75 (0.163-3.481)   0.716
OR, odds ratio; CI, confidence interval; APN, acute pyelonephritis; KT, kidney transplantation.
*Chronic renal failure, glomerulonephritis, nephrotic syndrome. 
†Urologic malignancy, urologic surgery, ureter stricture, vesico-ureteral reflux, polycystic kidney disease.Change of Antimicrobial Susceptibility in E. coli 
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compared to those of the other Korean studies reported in 
the recent 10 years (Table 3).7-11 In the present study, 8.8% 
ciprofloxacin resistance rate for the uncomplicated APN 
patients is relatively lower than that of the other previous 
reports. In order to help readers judge the reliability of this 
study, the antimicrobial susceptibility of E. coli isolates 
from stool cultures of general healthy individuals in the com-
munity is worthy to be reviewed. Lee, et al.27 examined the 
antimicrobial resistance of 491 E. coli isolates from the 
stool cultures of 692 healthy adults in 2006, and showed 
that the resistance to trimethoprim-sulfamethoxazole, cipro-
floxacin, amikacin and cefotaxime was 21.8%, 7.6%, 1.8% 
and 1.6%, respectively. This is a very similar to that of the 
uncomplicated APN group sub-analysis in this study.
This study focused on proving the change of antimicrobi-
al resistance of pathogenic E. coli isolates of the communi-
ty since 2000, and showed that trimethoprim-sulfamethoxa-
zole susceptibility was significantly improved, and that of 
gentamicin and third generation cephalosporin was signifi-
cantly worsened. The change of ciprofloxacin resistance 
showed an aggravated trend. 
The result presented herein is similar to the phenomena 
observed in the U.S., and this is most likely due to chang-
ing the recommended antibiotics for APN treatment.28 In 
fact, according to the 1999 revised treatment guideline,26 
the IDSA recommended not to administer trimethoprim-
sulfamethoxazole as empirical antibiotics. Instead, fluoro-
quinolone or extended spectrum cephalosporin or amino-
glycoside combined with ampicillin were recommended. 
However, because a treatment guideline that emphasized 
Based on the microbiologic epidemiology data, the 1999 
treatment guideline of the Infectious Disease Society of 
America (IDSA) recommended not to choose trimethoprim-
sulfamethoxazole as empirical antibiotic treatment for fe-
male adults with uncomplicated APN without first obtain-
ing antimicrobial susceptibility results.26
The 2008-2009 data of this study show that amoxicillin, 
ampicillin-sulbactam, trimethoprim-sulfamethoxazole, gen-
tamicin and ciprofloxacin have resistance more than 20%. 
In other words, not only trimethoprim-sulfamethoxazole, 
but also ciprofloxacin may not be recommended for use in 
Korea as empirical agents without first obtaining antimicro-
bial susceptibility data.
However, the results revealed quite a different picture if 
the data from 2008-2009 were analyzed according to un-
complicated APN and complicated APN. The antimicrobial 
resistance of the complicated APN patient group was rela-
tively high. Especially, ciprofloxacin resistance was as high 
as 30.6%, therefore, it could be an improper or unsafe em-
pirical antibiotic for complicated APN patients who have a 
relatively high risk of serious complications. However, for 
the uncomplicated APN patient group, the antimicrobial re-
sistance rate was relatively low and that of ciprofloxacin 
was low at 8.8%. Consequently, ciprofloxacin is still a safe 
treatment option as an empirical agent for uncomplicated 
APN patients unless they have a very severe and problem-
atic condition such as septic shock or progressive multi-or-
gan failure. 
In this study, the antimicrobial susceptibility results of the 
349 E. coli isolated during the 2008-2009 year period were 
Table 3. Antimicrobial Susceptibility of E. coli  from the Past Korean Studies of Community-Onset UTI
Reference Year
Study sample 
(location/gender/
diagnostic category)
n
Antimicrobial susceptibility (%)
AMC AP-BLI GM AMK SXT CPFX 3Ceph IMPM
Wie, et al.
7 2001-2006 Inpatients/female/
  APN 554 38.3 44.8 
(AMCSB) 81.3 98.7 62.1 86.3 99.5 
(CTX) 100
Kim, et al.
8 2006-2007 All/female/APN & 
  cystitis 387 - - - - 68.2 69.8 94.3 
(CTX) -
Hwang, et al.
9 1999-2001 Outpatients/all/
  uncomplicated APN   59 31.1 - 83.6 - 42.6 88.0 100 
(CTX) -
Kim, et al.
10 2002-2004 Inpatients/all/
  APN 217 29.7 - 83.1 99.1 60.3 80.5 97.2 
(CTRX) 100
Kim, et al.
11 2005 All/all/APN & 
  cystitis 440 31.0 - 75.7 98.9 68.0 70.2 93.4 
(CTX) 100
Present study 2008-2009 All/female/APN 349 36.4 77.1 
(AMXCV) 76.2 100 67.9 76.5 95.1 
(CTX) 100
UTI, urinary tract infection; APN, acute pyelonephritis; AMC, ampicillin; AP-BLI, aminopenicillin and beta-lactamase inhibitor; GM, gentamicin; AMK, ami-
kacin; SXT, trimethoprim-sulfamethoxazole; CPFX, ciprofloxacin; 3Ceph, third generation cephalosporin; IMPM, imipenem; AMSCB, ampicillin-sulbactam; 
AMXCV, amoxicillin-clavulanate; CTX, cefotaxime; CTRX, ceftriaxone.Seung-Kwan Lim, et al.
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be infected with susceptible organisms. Therefore, if the 
data included only patients who had a positive culture, this 
might exaggerate the results to be worse than that of the 
general population. In fact, similar Korean studies in the 
past had about a 54-68% average rate of positive urine cul-
tures.9,10,29 Finally, the study design is a retrospective analy-
sis of the medical records, therefore, our study has a limit 
that the data for the disease history or antibiotic administra-
tion might have relatively low reliability.
This research indicates that antibiotic treatment for com-
munity-onset APN patients should be approached accord-
ing to different specific patient groups and these patients 
should not be uniformly treated. In other words, the com-
munity-onset APN patients have heterogeneous antimicro-
bial resistant organism infections. Therefore, it will help to 
treat APN patients if they are classified by the risk of hav-
ing an antimicrobial resistant organism infection. In Korea, 
ciprofloxacin is still useful as an empirical antimicrobial 
agent for uncomplicated APN patients. However, for com-
plicated APN patients, administration of extended spectrum 
cephalosporins, such as ceftriaxone or cefotaxime, will be a 
safer decision, if the disease is severe. 
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fluoroquinolone has been published and widely distributed, 
the number of prescriptions for fluoroquinolone has in-
creased, and the number of prescriptions for trimethoprim-
sulfamethoxazole has decreased.28 The changing prescription 
patterns of antibiotics have caused the changing antimicrobial 
susceptibility patterns of community pathogens, therefore, 
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